Associations of Regional Brain Structural Differences With Aging, Modifiable Risk Factors for Dementia, and Cognitive Performance

Hideaki Suzuki, MD, PhD; Ashwin V. Venkataraman, MD; Wenjia Bai, DPhil; Florian Guitton, BSc; Yike Guo, PhD; Abbas Dehghan, MD, PhD, FESC; Paul M. Matthews, DPhil, FRCP, FMedSci; for the Alzheimer’s Disease Neuroimaging Initiative

Abstract

**IMPORTANCE** Identifying brain regions associated with risk factors for dementia could guide mechanistic understanding of risk factors associated with Alzheimer disease (AD).

**OBJECTIVES** To characterize volume changes in brain regions associated with aging and modifiable risk factors for dementia (MRFD) and to test whether volume differences in these regions are associated with cognitive performance.

**DESIGN, SETTING, AND PARTICIPANTS** This cross-sectional study used data from UK Biobank participants who underwent T1-weighted structural brain imaging from August 5, 2014, to October 14, 2016. A voxelwise linear model was applied to test for regional gray matter volume differences associated with aging and MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use). The potential clinical relevance of these associations was explored by comparing their neuroanatomical distributions with the regional brain atrophy found with AD. Mediation models for risk factors, brain volume differences, and cognitive measures were tested. The primary hypothesis was that common, overlapping regions would be found. Primary analysis was conducted on April 1, 2018.

**MAIN OUTCOMES AND MEASURES** Gray matter regions that showed relative atrophy associated with AD, aging, and greater numbers of MRFD.

**RESULTS** Among 8312 participants (mean [SD] age, 62.4 [7.4] years; 3959 [47.1%] men), aging and 4 major MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use) had independent negative associations with specific gray matter volumes. These regions overlapped neuroanatomically with those showing lower volumes in participants with AD, including the posterior cingulate cortex, the thalamus, the hippocampus, and the orbitofrontal cortex. Associations between these MRFD and spatial memory were mediated by differences in posterior cingulate cortex volume ($\beta = 0.0014; SE = 0.0006; P = .02$).

**CONCLUSIONS AND RELEVANCE** This cross-sectional study identified differences in localized brain gray matter volume associated with aging and MRFD, suggesting regional vulnerabilities. These differences appeared relevant to cognitive performance even among people considered cognitively healthy.
Introduction

The prevalence of dementia, estimated in most countries to be 5% to 7% among people 60 years and older, is increasing globally with greater longevity. A likely contributor to rising incidence in dementia other than aging is the global increase in lifestyle diseases, such as hypertension, diabetes, and obesity. These and other modifiable risk factors for dementia (MRFD), such as alcohol use, additively contribute approximately one-third of the total risk of Alzheimer disease (AD) although the pathophysiological mechanisms are not well understood.

Brain atrophy is the most prominent characteristic of brain structural abnormalities in AD. Subtle structural differences similar to those later expressed with AD can be identified in the brains of people who are cognitively healthy (CH) at least a decade before any expected onset of AD. Atrophy in brain regions independently associated with early pathology of AD is associated with cognitive decline in individuals who are otherwise CH. These and related observations suggest that brain structure is sensitive to factors contributing to late-life cognitive impairment and dementia.

The brain also atrophies with increasing age at an mean rate of 0.5% per year after age 40 years, although rates of volume loss vary considerably between individuals. Possible explanations for these differences include both genetic variation and differences in exposures to environmental or lifestyle factors that themselves accelerate brain atrophy. Numerous neuroimaging experiments have revealed that the brain atrophy is accelerated by hypertension, diabetes, obesity, smoking, low educational attainment, high alcohol intake, and inadequate sleep. However, whether aging and MRFD only influence brain regions sensitive to earlier neuropathological changes with AD or broadly affect all regions of the brain still remains unclear.

We addressed this question using data from the UK Biobank (UKB) and Alzheimer's Disease Neuroimaging Initiative (ADNI). The UKB is a resource for prospective, longitudinal brain magnetic resonance images (MRIs) associated with detailed health and lifestyle information characterizing large numbers of people recruited from general practice registers across the United Kingdom. The primary purpose of our study was to determine whether aging and MRFD had independent associations with regional gray matter volumes (GMVs) also associated with AD. We also tested whether associations of aging and multiple MRFD on cognitive impairment are associated with mediation by these regional GMV differences.

Methods

Study Participants

The UKB recruited approximately 500,000 participants aged 40 to 69 years across Great Britain between March 13, 2006, to October 1, 2010. Since 2014, a subset of participants underwent brain MRI. For this cross-sectional study, we used a data set that included participants who underwent structural brain MRI from August 5, 2014, to October 14, 2016. The UKB received National Research Ethics Approval. All participants provided written informed consent. This study was conducted under terms of UKB access approval and is reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

To characterize gray matter regions associated with AD, we used brain MRIs from 100 patients with AD and 133 age-, sex-, and race/ethnicity-matched healthy controls contributing to the ADNI resource. The ADNI was launched in 2003 as a public-private partnership, led by Michael W. Weiner, MD. The primary goal of ADNI has been to determine whether serial MRI, positron emission tomography, other biological markers, and clinical and neuropsychological assessments can be combined to measure the progression of mild cognitive impairment and early AD. The ADNI received US ethical approval from 58 study locations, with all participants providing written informed consent. Inclusion and exclusion criteria for the ADNI cohort have been described previously.
Baseline Characteristics
Information on age, sex, race/ethnicity, MRFD (i.e., hypertension, diabetes, obesity, frequency of alcohol use, current smoking, and sleep duration), educational attainment, and history of neurological or psychiatric disease were reported by UKB participants at the time of the imaging assessment. Definitions of MRFD are provided in the eAppendix in the Supplement.\textsuperscript{25,26,38-41} Information on histories of neurological or psychiatric diseases was obtained from the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision\textsuperscript{42} codes in the UKB database (F0-509, F540, F590, F700-890, F990, G40-119, G130-239, G300-419, G460-468, G800-948, G972, I600-I698, and I780). Data on age, sex, and race/ethnicity also were collected from the ADNI database.\textsuperscript{37}

Cognitive Assessment
We used the number of uncorrected matches in the pair matching test,\textsuperscript{43} the mean time to correctly identify matches in the reaction time test,\textsuperscript{44} and the number of questions attempted within the time limit for assessment of spatial memory, reaction time, and fluid intelligence\textsuperscript{45} as described previously\textsuperscript{46} (see eAppendix in the Supplement). Cognitive assessment data were acquired on the same day of brain MRI acquisition.

Brain MRI Acquisition and Analysis
The MRI acquisition and processing are described in the eAppendix in the Supplement.\textsuperscript{47-52} Briefly, gray matter probabilistic maps were segmented from acquired UKB and ADNI T1 MRIs and normalized to the same standard Montreal Neurological Institute space for voxelwise analyses.

Statistical Analysis
All analyses were performed using Stata statistical software version 14 (StataCorp) unless otherwise stated. Distributions of continuous variables are shown in eFigure 1 in the Supplement. Normally distributed continuous variables were analyzed using the t test, continuous variables which were not distributed normally were analyzed using the Mann-Whitney test, and nominal variables were analyzed using the Pearson χ\textsuperscript{2} statistic. P values were 2-tailed, and significance levels were set at less than .05 unless otherwise indicated. Familywise error rate (FWER)-corrected P values less than .05 were used as a significance threshold in voxelwise analyses owing to multiple voxel comparisons.\textsuperscript{53}

We first demonstrated independent associations of age and MRFD with total GMV in the UKB cohort (eAppendix in the Supplement). The correlation coefficients across age, MRFD, and the other covariates are shown in eTable 1 in the Supplement. To define the gray matter regions in which volume differences were associated with aging and the MRFD, we performed a voxelwise linear mixed analysis\textsuperscript{51,54} using a model in which each voxel of the normalized gray matter maps was a dependent variable and age and MRFD were independent variables adjusted for sex, race/ethnicity, educational attainment, and intracranial volume (ICV). We separately contrasted GMVs in the ADNI AD and CH groups on a voxelwise basis to create a binarized mask describing regions showing relative atrophy with AD. These 2 voxelwise analyses in a common brain space allowed for testing whether gray matter regions in which volume differed with aging and MRFD in the UKB population overlapped with those associated with regional atrophy in AD for the ADNI population. This primary analysis was conducted on April 1, 2018.

We also tested whether the association between age and GMV was modified by MRFD in the UKB cohort by entering the product of age and the number of MRFD in the linear regression model with total GMV as the outcome. This interaction was visualized using regressions between normalized total GMV and age for variable numbers of MRFD. Normalized total GMV was calculated for each regression relative to the total GMV to ICV ratio at age 50 years.

Finally, we tested whether associations of aging and multiple MRFD with cognitive impairment were associated with mediation by their brain volume differences using structural equation modeling. Before conducting structural equation modeling, we tested associations of cognitive test
scores with brain regions showing differences with aging and MRFD (eAppendix in the Supplement). Associations of aging and MRFD with cognitive test scores also were tested (eAppendix in the Supplement). After testing these associations, structural equation modeling was used to test for mediation of the association of age and numbers of MRFD with spatial memory score by the volume of the posterior cingulate cortex. We chose to explore this mediation using spatial memory score and posterior cingulate cortex volume because of the observed associations of spatial memory with both the number of MRFD and posterior cingulate cortex volume. Direct associations of the MRFD with cognitive function also were tested. Goodness of the model fit was tested using $\chi^2$, root mean square error of approximation, Akaike information criterion, comparative fit index, and Tucker-Lewis index.

Results

Characteristics of Participants Selected

Among 9932 participants recruited from the UKB aged 40 to 69 years who had brain MRI data, we excluded 507 individuals lacking cognitive test data, 628 lacking baseline characterization, and 485 individuals with neurological or psychiatric disease. Characteristics of the remaining 8312 participants (mean [SD] age, 62.4 [7.4] years; 3959 [47.1%] men) whose brain images were used in this study are described in the Table. Compared with included participants, the UKB imaging cohort participants

Table. Participants Characteristics

| Characteristic | UK Biobank Cohort, No. (%) | Excluded Participants, No./Total No. (%) | ADNI Cohort, No. (%) | Patients With AD (n = 100) | Individuals Who Were CH (n = 133) |
|----------------|-----------------------------|------------------------------------------|---------------------|---------------------------|-------------------------------|
| Nonmodifiable factors | | | | | |
| Age, mean (SD), y | 62.4 (7.4) | 63.6 (7.7) | 74.6 (8.1) | 73.4 (6.3) |
| Men | 3959 (47.6) | 770/1620 (47.5) | 57 (57.0) | 65 (48.9) |
| White | 8097 (97.4) | 1518/1584 (95.8) | 117 (89.0) | 89 (88.0) |
| Intracranial volume, mean (SD), mL | 1547.5 (149.7) | 1556.0 (151.6) | 1500.1 (169.5) | 1488.3 (148.6) |
| Overall brain volume measures, mean (SD), mL | | | | |
| Total brain | 1120.4 (110.0) | 1100.0 (113.5) | 955.5 (112.6) | 1013.9 (116.8) |
| Total gray matter | 664.6 (67.0) | 651.2 (68.9) | 557.4 (71.9) | 604.4 (75.3) |
| Total white matter | 455.7 (52.9) | 448.8 (54.5) | 398.1 (51.0) | 409.4 (52.1) |
| Modifiable risk factors for dementia | | | | | |
| Hypertension | 4236 (49.0) | 718/1138 (63.1) | NA | NA |
| Diabetes | 400 (4.8) | 114/1530 (7.5) | NA | NA |
| Obesity | 1515 (18.2) | 385/1590 (24.2) | NA | NA |
| Current smoking | 286 (3.4) | 126/1527 (8.3) | NA | NA |
| Frequent alcohol use | 1478 (17.9) | 257/1549 (16.6) | NA | NA |
| Inadequate sleep | 968 (11.6) | 272/1532 (17.8) | NA | NA |
| Cognitive test scores and educational attainment | | | | | |
| Mini-Mental State Examination score, median (IQR) | NA | NA | 29 (29-30) | 23 (21-25) |
| Spatial memory score, median (IQR) | 3 (0-5) | 2 (0-4)* | NA | NA |
| Reaction time, median (IQR), ms | 566 (511-636) | 577 (520-655)* | NA | NA |
| Fluid intelligence score, mean (SD) | 8.82 (2.09) | 8.64 (2.14)* | NA | NA |
| College degree education | 3936 (47.4) | 564 (37.2)* | 1.05 (1.00-1.18)* | 1.43 (1.25-1.54)* |

Abbreviations: AD, Alzheimer disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CH, cognitively healthy; IQR, interquartile range; NA, not available.

* Includes data from 1550 participants.

+ Includes data from 1501 participants.

Answer includes data from 97 participants.

\* Includes data from 128 participants.

\* Includes data from 133 participants.
whose data were available but who were excluded were older by a mean of 1.2 years (95% CI, 0.8-1.6 years; \( P < .001 \)), were less likely to be white (8097 white participants [97.4%] vs 1518 white participants [95.8%]; \( P = .001 \)), and had higher prevalences of risk factors for late-life cognitive impairment, including hypertension (4236 participants [49.0%] vs 718 participants [63.1%]; \( P < .001 \)), diabetes (400 participants [4.8%] vs 114 participants [7.5%]; \( P < .001 \)), obesity (1515 participants [18.2%] vs 385 participants [24.2%]; \( P < .001 \)), current smoking (286 participants [3.4%] vs 126 participants [16.6%]; \( P < .001 \)), and inadequate sleep (986 participants [11.6%] vs 272 participants [17.8%]; \( P < .001 \)), and had lower prevalence of college education (3936 participants [47.4%] vs 564 participants [37.2%]; \( P < .001 \)). Additionally, compared with the included participants, excluded participants had a lower median (interquartile range [IQR]) score for spatial memory (3 [0-5] vs 2 [0-4]; \( P < .001 \)), higher median (IQR) reaction time (566 [511-636] milliseconds vs 577 [520-655] milliseconds; \( P < .001 \)), a lower mean (SD) fluid intelligence score (8.82 [2.09] vs 8.64 [2.14]; \( P < .001 \)), and lower mean ICV volume (difference, 11.5 mL; 95% CI, 3.5-19.5 mL; \( P = .005 \)), total brain volume, (difference, 20.4 mL; 95% CI, 14.5-26.2 mL; \( P < .001 \)), total GMV (difference, 13.5 mL; 95% CI, 9.9-17.0 mL; \( P < .001 \)), and total white matter volume (difference, 6.9 mL; 95% CI, 4.1-9.7 mL; \( P < .001 \)).

The Table also presents characteristics of patients with AD and age-, sex-, and race/ethnicity-matched individuals who were CH selected from the ADNI cohort to develop a gray matter image mask describing regions showing relative atrophy with AD. Lower total brain volume in individuals with AD compared with individuals who were CH (difference, 60.0 mL; 95% CI, 31.4-88.7 mL; \( P < .001 \)) was explained by lower total GMV alone (difference, 48.5 mL; 95% CI, 30.3-66.7 mL; \( P < .001 \)); the difference in total white matter volume between the groups was not significant (difference, 11.6 mL; 95% CI, -3.0 to 26.1 mL; \( P = .12 \)). Consistent with their diagnoses, participants with AD, compared with participants who were CH, had a lower mean Mini-Mental State Examination score (difference, 6.0; 95% CI, 5.0-7.0; \( P < .001 \)) and higher mean cerebral amyloid standardized uptake value (difference, 0.31; 95% CI, 0.25-0.37; \( P < .001 \)).

### Overlap of Regions Associated With AD With GMV Differences Explained by Aging and MRFD

We generated an image mask describing the distributions of regional brain volume differences in people with AD compared with people who were CH in the ADNI cohort. A voxelwise analysis showed that the differences were predominantly in the gray matter of the temporal, prefrontal, and posterior cingulate cortices (FWER-corrected \( P < .05 \)) (Figure 1A). Based on this observation, analyses of the associations of aging and MRFD with brain structure focused on analyses of GMV differences in the UKB cohort.

Before the regional analysis, we tested for the independent associations of aging and 6 MRFD with total GMV of participants in the UKB cohort. Greater age (\( b = -3.54 \) mL; SE = 0.06 mL; \( P < .001 \)) and all MRFD, including hypertension (\( b = -5.01 \) mL; SE = 0.06 mL; \( P < .001 \)), diabetes (\( b = -14.39 \) mL; SE = 2.12 mL; \( P < .001 \)), obesity (\( b = -4.70 \) mL; SE = 1.19 mL; \( P < .001 \)), frequent alcohol use (\( b = -4.90 \) mL; SE = 1.18 mL; \( P < .001 \)), current smoking (\( b = -6.06 \) mL; SE = 2.46 mL; \( P = .01 \)), and inadequate sleep (\( b = -2.91 \) mL; SE = 1.39 mL; \( P = .04 \)), were associated with lower GMV.

We then conducted a voxelwise regression analysis to spatially map these independent associations of age and those of each MRFD. Age-associated differences were found across most of the gray matter (FWER-corrected \( P < .05 \)) (Figure 1A). These differences extended beyond the gray matter regions in which volume differences associated with AD were found in the ADNI cohort, that is, only 84% of gray matter showing differences associated with age also showed differences associated with AD. Sex-associated differences in regional brain volume are shown in eFigure 2 in the Supplement (FWER-corrected \( P < .05 \)). Gray matter regions in which volume was lower in men compared with women overlapped those associated with AD and with age. Individual brain regions in which volume was associated with hypertension, diabetes, obesity, or frequent alcohol use are presented in Figure 2. Lower GMV associated with these 4 MRFD (ie, hypertension, diabetes,
obesity, and frequent alcohol use) (Figure 2) mapped within the larger volume showing GMV differences associated with age (FWER-corrected $P < .05$) (Figure 1B) and overlapped in the posterior cingulate cortex, the thalamus, the hippocampus, and the orbitofrontal cortex (Figure 1B). Neuroanatomically different gray matter regions showed negative volume associations with smoking or self-reported inadequate sleep. While the overall association of obesity with GMV was negative, smaller brain regions were found in which obesity was associated with higher GMV.

**Interaction of Aging With MRFD**

We tested for interactions among the associations of aging and MRFD with GMV. Introducing the product of age and the number of any of 4 MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use) for each individual improved the fit of the model ($b = -0.39 \text{ mL}; \text{SE} = 0.07 \text{ mL}; P < .001$), indicating that MRFD were associated with modifying the associations of age with total GMV.

---

**Figure 1. Gray Matter Regions With Volumes Associated With Alzheimer Disease, Age, and Modifiable Risk Factors for Dementia (MRFD)**

A, Brain volumes associated with dementia or age

B, Brain volumes associated with dementia, age, and MRFDs

C, Explanations for axial sections and colors

A, Purple regions define the overlap between gray matter regions showing lower volume associated with Alzheimer disease in the Alzheimer’s Disease Neuroimaging Initiative cohort (dark blue) and those associated with lower volumes with age in UK Biobank (light blue). B, Gray matter regions showing lower volume with dementia, greater age, and 1 or more (red), 2 (bright red), 3 (orange) or 4 (yellow) MRFD; the arrowheads indicate regions in the posterior cingulate cortex, the thalamus, the hippocampus, and the orbitofrontal cortex influenced by all of these factors (yellow). C, Positions of the axial slices selected for representations in A and B are shown.
Gray matter regions showing lower volume with hypertension (red) (A), lower volume with dementia (blue) (B), lower (green) and higher (yellow) volume with obesity (C), and lower volume with frequent alcohol use (magenta) (D).
Figure 3 shows a steeper slope for the fit lines in the presence of a greater number of MRFD, suggesting that the association of age with change in total GMV was more pronounced when individuals were exposed to more MRFD (no MRFD, −0.45%/y; 1 MRFD, −0.51%/y; 2 MRFD, −0.56%/y; 3–4 MRFD, −0.60%/y).

**Associations of Cognitive Test Scores With Brain Regions Showing Volume Differences With Aging and MRFD**

To better understand the potential clinical relevance of the GMV differences found in the generally healthy UKB population, we tested for voxelwise correlations in GMV with cognitive test performance (FWER-corrected \( P < .05 \)). Better scores of spatial memory performance were positively correlated with greater GMV in the posterior cingulate cortex. Lower fluid intelligence test performance was associated with lower volume in the posterior cingulate cortex, the thalamus, and the orbitofrontal cortex, and reaction time was negatively associated with GMV in the thalamus and the hippocampus (eFigure 3 in the Supplement).

**Associations of Aging and MRFD With Cognitive Test Scores**

We next tested for associations between aging and the 4 MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use) and differences in cognitive performance (eTable 2 in the Supplement). As expected, age was negatively associated with performance on tests of spatial memory (\( b = 0.06; SE = 0.004; P < .001 \)), reaction time (\( b = 3.77; SE = 0.15; P < .001 \)), and fluid intelligence (\( b = −0.03; SE = 0.003; P < .001 \)). Participants reporting all 4 MRFD had lower spatial memory performance scores than those without any MRFD (\( b = 1.52; SE = 0.63; P = .048 \)).

**Mediation Associated With Age or MRFD on Cognitive Performance by Brain Volume**

Based on the results of these brain volume and cognitive analyses, we used structural equation modeling to explore whether GMV in the posterior cingulate cortex could account for the associations of the 4 MRFD with lower spatial memory performance (Figure 4). There was no direct association of the 4 MRFD with spatial memory (\( β = −0.013; SE = 0.011; P = .23 \)). However, the model showed that the negative associations of the 4 MRFD with spatial memory were associated with a partial mediation by lower GMV in the posterior cingulate cortex (\( β = 0.0014; SE = 0.0006; P = .02 \)). There was a direct association of aging with spatial memory (\( β = 0.138; SE = 0.011; P < .001 \)), and lower GMV mediated this association (\( β = 0.009; SE = 0.0004; P = .003 \)).
Discussion

This cross-sectional study explored brain structural differences associated with aging and MRFD in a middle-aged UKB population who did not report a history of neurological or psychiatric diseases. Independent associations of 4 MRFD (ie, hypertension, diabetes, obesity, and frequent alcohol use) with differences in GMV associated with age were discovered. Aging and the 4 MRFD were associated with distinct regional differences in GMV, suggesting differences in sensitivity. We hypothesized that these differences reflect sensitivity to the early pathology leading to AD. As hypothesized, we found that regions of lower GMV associated with aging and exposures to the 4 MRFD individually overlapped with each other and with regions of expected GMV loss associated with AD in the posterior cingulate cortex, the thalamus, the hippocampus, and the orbitofrontal cortex. The associations of aging and MRFD with GMV were synergistic, indicating that aging-related GMV loss may be more severe with more MRFD. The clinical relevance of even these small GMV differences was supported by the observation that volume differences in the posterior cingulate cortex were associated with mediation of the associations of age and the 4 MRFD with spatial memory performance.

Two previous population-based studies have mapped brain regions associated with risk factors for dementia. A 2004 study by Taki et al included 769 Japanese participants with no known cognitive disorders with information of systolic blood pressure, alcohol use, and smoking. In that cohort, age was negatively correlated with overall brain volume; associations of focal GMV with systolic blood pressure and alcohol use were found, but they did not overlap, possibly because of limitations of power with the smaller sample size. A 2019 study by Cox et al explored associations of multiple vascular risk factors with brain structure in a UKB population different from ours. Smoking pack-years, hypertension, and higher aggregate vascular risk were associated with lower volumes of several gray matter regions, including the frontal and temporal cortex, and in subcortical gray matter structures. However, despite exploring risk factors chosen for their association with vascular disease, a striking observation in that study was the relatively weak association with direct imaging evidence of cerebrovascular disease in the population (white matter hyperintense volumes on T2-weighted images or an anatomical distribution of gray matter volume differences in regions of brain characteristically associated with large or small vessel disease). The greatest cortical differences associated with the risk factors were found in the anterior temporal cortex. Differences in white matter diffusivity, a measure associated with axon or myelin pathologies, were found throughout the brain. In our study, we used voxelwise rather than atlas region-based analyses and more stringent statistical criteria to achieve greater neuroanatomical precision in mapping structural associations. We also investigated the more general hypothesis that risk factors for late-life cognitive impairment may be associated with AD independent of any associations with vascular disease. While our conclusions agree in suggesting regional associations with some risk factors, most of which are also found in the studies by Taki et al and Cox et al, we do not interpret this regional association as reflecting brain structural changes associated with hypoperfusion or stroke.

Figure 4. Structural Equation Model Exploring Associations Among Age, Modifiable Risk Factors for Dementia (MRFD), Posterior Cingulate Cortex Volume, and Spatial Memory

Standardized correlation coefficients are shown. Solid lines indicate associations that were statistically significant; dashed line indicates no statistically significant association. The model had a χ² of 0.000, root mean square error of approximation less than 0.001, Akaike information criterion of 103857.9, comparative fit index of 1.000, and Tucker-Lewis index of 1.000.
We made 3 novel observations. First, we observed associations of aging and 4 MRFD exposures with GMV differences in common regions of the posterior cingulate cortex, the thalamus, the hippocampus, and the orbitofrontal cortex that correspond well with regions of early AD neuropathology. Reduced metabolism in the posterior cingulate cortex may precede clinical expression of AD. The hippocampus and thalami both show early neurofibrillary changes and can develop pathology associated with core amnestic symptoms. Widespread neurofibrillary tangle pathology in the orbitofrontal cortex also is found in patients with AD.

Second, associations of lower GMV with the MRFD were circumscribed within the larger brain regions showing a negative association of GMV with age. The additive contributions to AD risk from aging and these 4 MRFD may be explained by their anatomically overlapping independent associations with lower GMV. The GMV identified may have common associations with the apparently disparate risk factors through multiple mechanisms, such as involving local cell autonomous factor, properties of regional glial, dendritic, and synaptic networks or activity, or secondary associations mediated by longer range connectivities.

Third, we provided indirect evidence for the relevance of these observations for late-life cognitive impairments in a relatively healthy middle-aged population. We showed the jointly overlapping associations of lower GMV with aging and the 4 MRFD were found within the larger volume of relative atrophy seen in an independent population with AD. Consistent with earlier studies, we found independent associations of age and the 4 MRFD with lower cognitive performance. We also found that variation in an overlapping posterior cingulate cortex GMV associated with aging and the 4 MRFD was associated with mediating the negative associations of these risk factors with spatial memory. This association of the relative volume of the posterior cingulate cortex with spatial memory is consistent with a previous report.

Limitations
This study had limitations, including that it is based on cross-sectional analyses. Effect sizes may be lower than some previous aging studies that included participants 80 years or older because our population was relatively young for the expression of late-life cognitive impairment. The UKB population also is generally healthier than the wider UK population. We limited our analyses to regional GMV because this is more directly interpretable than diffusion tensor-based measures of white matter connectivities or functional MRI measures, for example. There also is a larger literature in which to contextualize the results. Limitations of the data available meant that MRFD were treated categorically rather than by severity and years of exposure to risk; analyses based on the latter would be expected to enhance power to detect differences. Additionally, because of limitations of study power, we only tested for linear associations with aging or MRFD.

Conclusions
This cross-sectional study found that aging and 4 MRFD, including hypertension, diabetes, obesity, and frequent alcohol use, were independently negatively associated with focal GMV in common regions of the posterior cingulate gyrus, the thalamus, the hippocampus, and the orbitofrontal cortex, which are also associated with the progression of AD. The associations observed in this generally healthy population highlight common regions of potential associations of risk factors with dementia and the association of these risk factors with mediation of their associations with reduced cognitive performance. We hypothesize that molecular pathology associated with the early biochemical phase of AD may be found in these regions. If the underlying mechanisms of association were identified and able to be targeted therapeutically, early stages of progression to AD could potentially be slowed or reversed.
ARTICLE INFORMATION

Accepted for Publication: October 21, 2019.
Published: December 11, 2019. doi: 10.1001/jamanetworkopen.2019.17257
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Suzuki H et al.
JAMA Network Open.

Corresponding Author: Hideaki Suzuki, MD, PhD, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo, Aoba, Sendai, 980-8574, Japan (hd.suzuki.1870031@cardio.med.tohoku.ac.jp).

Author Affiliations: Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan (Suzuki); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (Suzuki); Division of Brain Sciences, Department of Medicine, Imperial College London, London, United Kingdom (Suzuki, Venkataraman, Bai, Matthews); United Kingdom Dementia Research Institute, London, United Kingdom (Venkataraman, Matthews); Data Science Institute, Imperial College London, London, United Kingdom (Bai, Guitton, Guo); Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom (Dehghan).

Author Contributions: Drs Suzuki and Matthews had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Suzuki, Venkataraman, Guo, Matthews.

Acquisition, analysis, or interpretation of data: Suzuki, Venkataraman, Bai, Guitton, Dehghan, Matthews.

Drafting of the manuscript: Suzuki, Venkataraman, Matthews.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Suzuki, Venkataraman, Guo.

Obtained funding: Suzuki, Matthews.

Administrative, technical, or material support: Suzuki, Venkataraman, Guitton, Matthews.

Supervision: Guo, Matthews.

Conflict of Interest Disclosures: Dr Matthews reported serving as a member of the Steering Committee of the UK Biobank and as chair of the UK Biobank Imaging Working Group. No other disclosures were reported.

Funding/Support: This study was supported by grants from the Grants-in-Aid program from the Japan Society for the Promotion of Science (18K15410 [Dr Suzuki]); Research Fellowship from the Uehara Memorial Foundation, Medical Research Council (Dr Suzuki), the Alzheimer’s Society (440-AS-CTF-18-006 [Dr Venkataraman]), Edmond J. Safra Foundation, Lily Safra, UK Dementia Research Institute, National Institute of Health Research Biomedical Research Centre at Imperial, and Dementia Platforms UK (Dr Matthews). Data collection and sharing for this study were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) of the National Institutes of Health (U01 AG024904) and Department of Defense (W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from AbbVie, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Arclon Biotech, BioClinica, Biogen, Bristol-Myers Squibb, Ceretegr, Cogstate, Eisai, Elan Pharmaceuticals, Eli Lilly and Co, Euroimmun, F. Hoffmann-La Roche, Genentech, Fujirebio, GE Healthcare, IXICO, Janssen Alzheimer Immunotherapy Research and Development, Johnson and Johnson Pharmaceutical Research and Development, Lumosity, Lundbeck, Merck, Meso Scale Diagnostics, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals, Pfizer, Piramal Imaging, Servier, Takeda Pharmaceutical, and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: Alzheimer’s Disease Neuroimaging Initiative-I, ADNI-GO, ADNI-II, and ADNI-III investigators include Part A: Leadership and Infrastructure Principal Investigator (PI): Michael W. Weiner, MD, University of California, San Francisco; ATRI PI and Director of Coordinating Center Clinical Core: Paul Aisen, MD, University of Southern California; Executive Committee: Michael Weiner, MD, University of California, San Francisco; Paul Aisen, MD, University of Southern California; Ronald Petersen, MD, PhD, Mayo Clinic, Rochester; Clifford R. Jack Jr, MD, Mayo Clinic, Rochester; William Jagust, MD, University of California, Berkeley; John Q. Trojanowki, MD, PhD, University of Pennsylvania; Arthur W. Toga, PhD, University of Southern California; Laurel Beckett, PhD, University of California, Davis; Robert C. Green, MD, MPH, Brigham and Women’s Hospital/Harvard Medical School; Andrew J. Saykin, PsyD, Indiana University; John Morris, MD, Washington University in St Louis; and Leslie M. Shaw, University of Pennsylvania.
ADNI External Advisory Board members include Zaven Khachaturian, PhD, Prevent Alzheimer’s Disease 2020 (chair); Greg Sorensen, MD, Siemens; Maria Carrillo, PhD, Alzheimer’s Association; Lew Kuller, MD, University of Pittsburgh; Marc Raichle, MD, Washington University in St Louis; Steven Paul, MD, Cornell University; Peter Davies, MD, Albert Einstein College of Medicine of Yeshiva University; Howard Fillit, MD, AD Drug Discovery Foundation; Franz Hefti, PhD, Acumen Pharmaceuticals; David Holtzman, MD, Washington University in St Louis; M. Marcel Mesulam, MD, Northwestern University; William Potter, MD, National Institute of Mental Health; and Peter Snyder, PhD, Brown University.

ADNI-3 Private Partner Scientific Board: Veronika Logovinsky, MD, PhD, Eli Lilly (chair).

Data and Publications Committee members include Robert C. Green, MD, MPH, BWH/HMS (chair) Resource Allocation Review Committee; Tom Montine, MD, PhD, University of Washington (chair); Clinical Core Leaders: Ronald Petersen, MD, PhD, Mayo Clinic, Rochester (core PI); Paul Aisen, MD, University of Southern California Clinical Informatics and Operations; Gustavo Jimenez, MBS, University of Southern California; Michael Donohue, PhD, University of Southern California; Devon Gessert, BS, University of Southern California; Kelly Harless, BA, University of Southern California; Jennifer Salazar, MBS, University of Southern California; Yuliana Cabrera, BS, University of Southern California; Sarah Walter, MS, University of Southern California; and Lindsey Hergesheimer, BS, University of Southern California. Biostatistics Core Leaders and Key Personnel: Laurel Beckett, PhD, University of California, Davis (core PI); Danielle Harvey, PhD, University of California, Davis; and Michael Donohue, PhD, University of California, San Diego. MRI Core Leaders and Key Personnel: Clifford R. Jr, MD, Mayo Clinic, Rochester (core PI); Matthew Bernstein, PhD, Mayo Clinic, Rochester; Nick Fox, MD, University of London; Paul Thompson, PhD, University of California, Los Angeles School of Medicine; Norbert Schuff, PhD, University of California, San Francisco MRI; Charles DeCarli, MD, University of California, Davis; Bret Borowski, RT, Mayo Clinic; Jeff Gunter, PhD, Mayo Clinic; Matt Senjem, MS, Mayo Clinic; Prashanthi Vemuri, PhD, Mayo Clinic; David Jones, MD, Mayo Clinic; Kajal Kantarci, Mayo Clinic; and Chad Ward, Mayo Clinic. PET Core Leaders and Key Personnel: William Jagust, MD, University of California, Berkeley (core PI); Robert A. Koepp, PhD, University of Michigan; Norm Foster, MD, University of Utah; Eric M. Reiman, MD, Banner Alzheimer’s Institute; Kewei Chen, PhD, Banner Alzheimer’s Institute; Chet Mathis, MD, University of Pittsburgh; and Susan Landau, PhD, University of California, Berkeley.

Neuropathology Core Leaders include John C. Morris, MD, Washington University in St Louis; Nigel J. Cairns, PhD, FRCPath, Washington University in St Louis; Erin Franklin, MS, CCRP, Washington University in St Louis; and Lisa Taylor-Reinwald, BA, HTL, Washington University in St Louis.

American Society for Clinical Pathology (ASCP) - Past Investigator: Biomarkers Core Leaders and Key Personnel: Leslie M. Shaw, PhD, University of Pennsylvania School of Medicine; John Q. Trojanowski, MD, PhD, University of Pennsylvania School of Medicine; Virginia Lee, PhD, MBA, University of Pennsylvania School of Medicine; Magdalena Korecka, PhD, University of Pennsylvania School of Medicine; and Michal Figurski, PhD, University of Pennsylvania School of Medicine. Informatics Core Leaders and Key Personnel: Arthur W. Toga, Ph.D, University of Southern California (core PI); Karen Crawford, University of Southern California; and Scott Neu, PhD, University of Southern California. Genetics Core Leaders and Key Personnel: Andrew J. Saykin, PsyD, Indiana University; Tatiana M. Foroud, PhD, Indiana University; Steven Potkin, MD, University of California, Irvine; Li Shen, PhD, Indiana University; Kelley Faber, MS, CCRC, Indiana University; Sungeun Kim, PhD, Indiana University; and Kwangsik Nho, PhD, Indiana University. Initial Concept Planning and Development: Michael W. Weiner, MD, University of California, San Francisco; Lean Thal, MD, University of California, San Diego; and Zaven Khachaturian, PhD, Prevent Alzheimer’s Disease 2020. Early Project Proposal Development: Leon Thal, MD, University of California, San Diego; Neil Buckholtz, National Institute on Aging; Michael W. Weiner, MD, University of California, San Francisco; Peter J. Snyder, PhD, Brown University; William Potter, MD, National Institute of Mental Health; Steven Paul, MD, Cornell University; Marilyn Albert, PhD, Johns Hopkins University; Richard Frank, MD, PhD, Richard Frank Consulting; Zaven Khachaturian, PhD, Prevent Alzheimer’s Disease 2020; and John Hsiao, MD, National Institute on Aging.

Part B: Investigators by Site: Oregon Health & Science University: Joseph Quinn, MD; Lisa C. Silbert, MD; Betty Lind, BS; Jeffrey A. Kaye, MD (past investigator); Raina Carter, BA (past investigator); and Sara Dolen, BS (past investigator). University of Southern California: Lon S. Schneider, MD; Sonia Pawluczyk, MD; Mauricio Becerra, BS; Liberty Teodoro, RN; and Bryan M. Spann, DO, PhD (past investigator). University of California-San Diego: James Brewer, MD, PhD; Helen Vanderswag, RN; and Adam Fleisher, MD (past investigator). University of Michigan: Jaimie Ziolkowski, MA, BS, TLLP; Judith L. Heidebrink, MD, MS; and Joanne L. Lord, LPN, BA, CCRC (past investigator). Mayo Clinic, Rochester: Ronald Petersen, MD, PhD; Sara S. Mason, RN; Colleen S. Albers, RN; David Knapman, MD; and Kris Johnson, RN (past investigator). Baylor College of Medicine: Javier Villanueva-Meyer, MD; Valory Pavlik, PhD; Nathaniel Pacini, MA; Ashley Lamb, MA; Joseph S. Kass, MD, LD, FAAN; Rachelle S. Doody, MD (past investigator); Victoria Shibley, MS (past investigator). University of Southern California: Munir Choudhury, MBBS, MS (past investigator); Susan Rountree, MD (past investigator); and Mimi Dang, MD (past investigator). Columbia University Medical Center: Yaakov Stern, PhD; Lawrence S. Honig, MD, PhD; Karen L. Bell, MD; and Randy Yeh, MD, Washington.
Forest University Health Sciences; Kaycee M. Sink, MD, MAS; Mia Yang, MD; and Akiva Mintz, MD, PhD. Rhode Island Hospital: Brian R. Ott, MD; Geoffrey Tremont, PhD; and Lori A. Dailello, PharmD, ScM. Butler Hospital: Courtney Bodge, PhD; Stephen Salloway, MD, MS; Paul Malloy, PhD; Stephen Correa, PhD; and Athena Lee, PhD. University of California, San Francisco: Howard J. Rosen, MD; Bruce L. Miller, MD; and David Perry, MD. Medical University of South Carolina: Jacobo Mintzer, MD, MBA; Kenneth Spicer, MD, PhD; and David Bachman, MD. St Joseph's Health Care: Elizabeth Finger, MD; Stephen Pasternak, MD; Irina Rachinsky, MD; John Rodgers, MD; Andrew Kertesz, MD (past investigator); and Dick Drost, MD (past investigator). Nathan Kline Institute: Nunzio Pomara, MD; Raymundo Hernandez, MD; and Antero Sarrael, MD. University of Iowa College of Medicine. Delwyn D. Miller, PharmD, MD; Karen Ekstam Smith, RN; Hristina Koleva, MD; Ki Won Nam, MD; Hyungsuk Shim, MD; and Susan K. Schultz, MD (Past Investigator). Cornell University: Norman Relkin, MD, PhD; Gloria Chiang, MD; Michael Lin, MD; and Lisa Ravid, PhD. University of South Florida Health Byrd Alzheimer's Institute: Amanda Smith, MD; Christi Leach, MD; Balebail Ashok Raj, MD (Past Investigator); and Kristin Fargher, MD (Past Investigator).

DOD ADNI investigators include Part A: Leadership and Infrastructure Principal Investigator: Michael W. Weiner, MD, University of California, San Francisco; ATRI PI and Director of Coordinating Center Clinical Core: Paul Aisen, MD, University of Southern California; Executive Committee: Michael Weiner, MD, University of California, San Francisco; Paul Aisen, MD, University of Southern California; Ronald Petersen, MD, PhD, Mayo Clinic, Rochester; Robert C. Green, MD, MPH, Brigham and Women’s Hospital/Harvard Medical School; Danielle Harvey, PhD, University of California, Davis; Clifford R. Jack Jr, MD, Mayo Clinic, Rochester; William Jagust, MD, University of California, Berkeley. John C. Morris, MD, Washington University in St Louis; Andrew J. Saykin, PsyD, Indiana University; Leslie M. Shaw, PhD, Perelman School of Medicine, University of Pennsylvania; Arthur W. Toga, PhD, University of Southern California; John Q. Trojanowki, MD, PhD, Perelman School of Medicine, University of Pennsylvania; Psychological Evaluation/PTSD Core: Thomas Neylan, MD, University of California, San Francisco; Traumatic Brain Injury/TBI Core: Jordan Grafman, PhD, Rehabilitation Institute of Chicago, Feinberg School of Medicine, Northwestern University; Data and Publication Committee: Robert C. Green, MD, MPH BW/HMS (chair); Resource Allocation Review Committee: Tom Montine, MD, PhD, University of Washington (chair); Clinical Core Leaders: Michael Weiner MD (core PI); Ronald Petersen, MD, PhD, Mayo Clinic, Rochester (core PI); Paul Aisen, MD, University of Southern California; Clinical Informatics and Operations: Gustavo Jimenez, MBS, University of Southern California; Michael Donohue, PhD, University of Southern California; Devin Gessert, BS, University of Southern California; Kelly Harless, BA, University of Southern California; Jennifer Salazar, MBS, University of Southern California; Juliana Cabrera, BS, University of Southern California; Sarah Walter, MSc, University of Southern California; Lindsey Hergesheimer, BS, University of Southern California; San Francisco Veterans Affairs Medical Center; Thomas Neylan, MD, University of California, San Francisco; Jacqueline Hayes, University of California, San Francisco; Shannon Finley, University of California, San Francisco; Biostatistics Core Leaders and Key Personnel: Danielle Harvey, PhD, University of California, Davis (core PI); Michael Donohue, PhD, University of California, San Diego; MRI Core Leaders and Key Personnel: Clifford R. Jack Jr, MD, Mayo Clinic, Rochester (core PI); Matthew Bernstein, PhD, Mayo Clinic, Rochester; Bret Borowski, RT, Mayo Clinic, Jeff Gunter, PhD, Mayo Clinic; Matt Senjem, MS, Mayo Clinic, Kejal Kantarci, Mayo Clinic; Chad Ward, Mayo Clinic; PET Core Leaders and Key Personnel: William Jagust, MD, University of California, Berkeley (core PI); Robert A. Koeppe, PhD, University of Michigan; Norm Foster, MD, University of Utah; Eric M. Reiman, MD, Banner Alzheimer’s Institute; Kewei Chen, PhD, Banner Alzheimer’s Institute; Susan Landau, PhD, University of California, Berkeley; Neuropathology Core Leaders: John C. Morris, MD, Washington University in St Louis; Nigel J. Cairns, PhD, FRCPath, Washington University in St Louis; Erin Householder, MS, Washington University in St Louis; Biomarkers Core Leaders and Key Personnel: Leslie M. Shaw, PhD, Perelman School of Medicine, University of Pennsylvania; John Q. Trojanowki, MD, PhD, Perelman School of Medicine, University of Pennsylvania; Virginia Lee, PhD, MBA, Perelman School of Medicine, University of Pennsylvania; Magdalena Korecka, PhD, Perelman School of Medicine, University of Pennsylvania; Michal Figurski, PhD, Perelman School of Medicine, University of Pennsylvania; Informatics Core Leaders and Key Personnel: Arthur W. Toga, PhD, University of California, San Francisco (core PI); Karen Crawford, University of Southern California; Scott Neu, PhD, University of Southern California; Genetics Core Leaders and Key Personnel: Andrew J. Saykin, PsyD, Indiana University; Tatiana M. Foroud, PhD, Indiana University; Steven Potkin, MD, University of California, Irvine; Li Shen, PhD, Indiana University; Kelley Faber, MS, CCRC, Indiana University; Sungeun Kim, PhD, Indiana University; Kwangsik Nho, PhD, Indiana University; Initial Concept Planning and Development: Michael W. Weiner, MD, University of California, San Francisco; Karl Friedl, Department of Defense (retired).

Part B: Investigators by Site: University of Southern California: Lon S. Schneider, MD, MS; Sonia Pawluczyk, MD; and Mauricio Becerra. University of California, San Diego: James Brewer, MD, PhD; and Helen Vanderswag, RN. Columbia University Medical Center: Yaakov Stern, PhD; Lawrence S. Honig, MD, PhD; and Karen L. Bell, MD. Rush University Medical Center: Debra Fleischman, PhD; Konstantinos Arfanakis, PhD; and Raj C. Shah, MD. Wien Center: Ranjan Dua, MD (PI); Daniel Varon, MD (co-PI); and Maria T Greig, HP (coordinator). Duke University Medical Center: P. Murali Doraiswamy, MBBS; Jeffrey R. Petrella, MD; and Olga James, MD. University of Rochester Medical Center: Anton P. Porsteinsson, MD (director); Bonnie Goldstein, MS, NP (coordinator); and Kimberly S.
REFERENCES

1. World Health Organization. Dementia: A Public Health Priority. Geneva, Switzerland: World Health Organization; 2012.

2. World Health Organization. A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis. Geneva, Switzerland: World Health Organization; 2013.

3. World Health Organization. Global Report on Diabetes. Geneva, Switzerland: World Health Organization; 2016.

4. Afshin A, Forouzanfar MH, Reitsma MB, et al; GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 Years. N Engl J Med. 2017;377(1):13-27. doi:10.1056/NEJMoai1614362
5. Harwood DG, Kalechstein A, Barker WW, et al. The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer’s disease. Int J Geriatr Psychiatry. 2010;25(5):511-518. doi:10.1002/gps.2372

6. Norton S, Matthews FE, DE B, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788-794. doi:10.1016/S1474-4422(14)70136-X

7. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

8. Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395-1402. doi:10.1212/WNL.0b013e3182166e96

9. Dickerson BC, Wolk DA; Alzheimer’s Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012;78(2):84-90. doi:10.1212/WNL.0b013e31823efc6c

10. Svennerholm L, Bostöm K, Jungbjer B. Changes in weight and composition of major membrane components of human brain during the span of adult human life of Swedes. Acta Neuropathol. 1997;94(4):345-352. doi:10.1007/s004010050717

11. Raz N, Gunning FM, Head D, et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex. 1997;7(3):268-282. doi:10.1093/cercor/7.3.268

12. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of aging in 465 normal adult human brains. Neuroimage. 2001;14(1)(pt 1):21-36. doi:10.1006/nimg.2001.0786

13. Taki Y, Goto R, Evans A, et al. Voxel-based morphometry of human brain with age and cerebrovascular risk factors. Neurobiol Aging. 2004;25(4):455-463. doi:10.1016/j.neurobiolaging.2003.09.002

14. Taki Y, Kinomura S, Sato K, Goto R, Kawashima R, Fukuda H. A longitudinal study of gray matter volume decline with age and modifying factors. Neurobiol Aging. 2011;32(5):907-915. doi:10.1016/j.neurobiolaging.2009.05.003

15. Fotenes AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology. 2005;64(6):1032-1039. doi:10.1212/01.WNL.0000154530.72969.11

16. Cook AH, Sridhar J, Ohm D, et al. Rates of cortical atrophy in adults 80 years and older with superior vs average episodic memory. JAMA. 2017;317(13):1373-1375. doi:10.1001/jama.2017.0627

17. Strassburger TL, Lee HC, Daly EM, et al. Interactive effects of age and hypertension on volumes of brain structures. Stroke. 1997;28(7):1410-1417. doi:10.1161/01.STR.28.7.1410

18. Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension. 2004;44(1):29-34. doi:10.1161/101.HYPO000132475.32317bb

19. Gianaros PJ, Greer PJ, Ryan CM, Jennings JR. Higher blood pressure predicts lower regional grey matter volume: consequences on short-term information processing. Neuroimage. 2006;31(2):754-765. doi:10.1016/j.neuroimage.2006.01.003

20. Cox SR, Lyall DM, Ritchie SJ, et al. Associations between vascular risk factors and brain MRI indices in UK Biobank. Eur Heart J. 2019;40(28):2290-2300. doi:10.1093/eurheartj/ehz100

21. Debbete S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77(5):461-468. doi:10.1212/WNL.0b013e318227b227

22. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care. 2013;36(12):4036-4042. doi:10.2337/dc13-0143

23. Biessels GJ, Reijmer YD. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetologia. 2014;63(7):2244-2252. doi:10.2337/db14-0348

24. Srinivasan RN, Rossetti HC, Gupta MK, et al. Cardiovascular risk factors associated with smaller brain volumes in regions identified as early predictors of cognitive decline. Radiology. 2016;281(1):198-204. doi:10.1148/radiol.2015142488

25. Pannaccioni N, Del Parigi A, Chen K, Le DS, Reiman EM, Tatnall PA. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage. 2006;31(4):1419-1425. doi:10.1016/j.neuroimage.2006.01.047

26. Taki Y, Kinomura S, Sato K, et al. Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring). 2008;16(1):119-124. doi:10.1038/oby.2007.4

27. Franklin TR, Wetherill RR, Jagannathan K, et al. The effects of chronic cigarette smoking on gray matter volume: influence of sex. PLoS One. 2014;9(8):e104102. doi:10.1371/journal.pone.0104102
28. Fritz HC, Wittfeld K, Schmidt CO, et al. Current smoking and reduced gray matter volume: a voxel-based morphometry study. *Neuropsychopharmacology*. 2014;39(11):2594-2600. doi:10.1038/npp.2014.112

29. Foubert-Samier A, Catheline G, Amieva H, et al. Education, occupation, leisure activities, and brain reserve: a population-based study. *Neurobiol Aging*. 2012;33(2):423.e15-423.e25. doi:10.1016/j.neurobiolaging.2010.09.023

30. Liu Y, Julkunen V, Paajanen T, et al; AddNeuroMed Consortium. Education increases reserve against Alzheimer’s disease—evidence from structural MRI analysis. *Neuroradiology*. 2012;54(9):929-938. doi: 10.1007/s00234-012-1005-0

31. Taki Y, Kinomura S, Sato K, et al. Both global gray matter volume and regional gray matter volume negatively correlate with lifetime alcohol intake in non-alcohol-dependent Japanese men: a volumetric analysis and a voxel-based morphometry. *Alcohol Clin Exp Res*. 2006;30(6):1045-1050. doi:10.1111/j.1530-0277.2006.00118.x

32. Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. *BMJ*. 2017;357:j2353. doi:10.1136/bmj.j2353

33. Riemann D, Voderholzer U, Spiegelhalder K, et al. Chronic insomnia and MRI-measured hippocampal volumes: a pilot study. *Sleep*. 2007;30(8):955-958. doi:10.1093/sleep/30.8.955

34. Spira AP, Gonzalez CE, Venkatraman VK, et al. Sleep duration and subsequent cortical thinning in cognitively normal older adults. *Sleep*. 2016;39(5):1121-1128. doi:10.5665/sleep.5768

35. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779

36. Miller KL, Alfaro-Almagro F, Bangertner NK, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Not Neurosci*. 2016;19(11):1523-1536. doi:10.1038/nn.4393

37. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology*. 2010;74(3):201-209. doi:10.1212/WNL.0b013e3181cb3e25

38. Biobank UK. Blood pressure: version 1.0. https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/Bloodpressure.pdf. Accessed November 4, 2019.

39. Suzuki H, Gao H, Bai W, et al. Abnormal brain white matter microstructure is associated with both pre-hypertension and hypertension. *PloS One*. 2017;12(11):e0187600. doi:10.1371/journal.pone.0187600

40. Smith DJ, Nicholl B, Cullen B, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PloS One*. 2013;8(11):e75362. doi:10.1371/journal.pone.0075362

41. Tsai TC, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Long sleep duration associated with a higher risk of increased arterial stiffness in males. *Sleep*. 2014;37(8):1315-1320. doi:10.5665/sleep.3920

42. World Health Organization. *International Statistical Classification of Diseases, Tenth Revision (ICD-10)*. Geneva, Switzerland: World Health Organization; 1992.

43. Biobank UK. Touch-screen pairs memory test: version 1.2. http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/Pairs.pdf. Accessed November 4, 2019.

44. Biobank UK. Touch-screen test of reaction time (Snap): version 1.1. https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/Snap.pdf. Accessed October 30, 2019.

45. Biobank UK. Touch-screen fluid intelligence test: version 1.1. http://biobank.ndph.ox.ac.uk/crystal/crystal/docs/Fluidintelligence.pdf. Accessed October 30, 2019.

46. Lyall DM, Cullen B, Allerhand M, et al. Cognitive Test Scores in UK Biobank: data reduction in 480,416 participants and longitudinal stability in 20,346 participants. *PloS One*. 2016;11(4):e0154222. doi:10.1371/journal.pone.0154222

47. Biobank UK. Brain imaging documentation: version 1.2. http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf. Accessed October 30, 2019.

48. Wyman BT, Harvey DJ, Crawford K, et al; Alzheimer’s Disease Neuroimaging Initiative. Standardization of analysis sets for reporting results from ADNI MRI data. *Alzheimers Dement*. 2013;9(3):332-337. doi:10.1016/j.jalz.2012.06.004

49. Jack CR Jr, Barnes J, Bernstein MA, et al. Magnetic resonance imaging in Alzheimer’s Disease Neuroimaging Initiative 2. *Alzheimers Dement*. 2015;11(7):740-756. doi:10.1016/j.jalz.2015.05.002

50. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage*. 2007;38(1):95-113. doi:10.1016/j.neuroimage.2007.07.007
Brain Regions Associated With Aging and Modifiable Risk Factors for Dementia

JAMA Network Open. 2019;2(12):e1917257. doi:10.1001/jamanetworkopen.2019.17257

51. Suzuki H, Sumiyoshi A, Matsumoto Y, et al. Structural abnormality of the hippocampus associated with depressive symptoms in heart failure rats. *Neuroimage*. 2015;105:84-92. doi:10.1016/j.neuroimage.2014.10.040

52. Suzuki H, Matsumoto Y, Ota H, et al. Hippocampal blood flow abnormality associated with depressive symptoms and cognitive impairment in patients with chronic heart failure. *Circ J*. 2016;80(8):1773-1780. doi:10.1253/circj.CJ-16-0367

53. Nichols T, Hayasaka S. Controlling the familywise error rate in functional neuroimaging: a comparative review. *Stat Methods Med Res*. 2003;12(5):419-446. doi:10.1191/0962280203sm341ra

54. Suzuki H, Matsumoto Y, Ota H, et al. Structural brain abnormalities and cardiac dysfunction in patients with chronic heart failure. *Eur J Heart Fail*. 2018;20(5):936-938. doi:10.1002/ejhf.1104

55. Payabvash S, Souza LC, Wang Y, et al. Regional ischemic vulnerability of the brain to hypoperfusion: the need for location specific computed tomography perfusion thresholds in acute stroke patients. *Stroke*. 2011;42(5):1255-1260. doi:10.1161/STROKEAHA.110.600940

56. Enzinger C, Smith S, Fazekas F, et al. Lesion probability maps of white matter hyperintensities in elderly individuals: results of the Austrian stroke prevention study. *J Neurol*. 2006;253(8):1064-1070. doi:10.1007/s00415-006-0164-5

57. Lindquist MA, Mejia A. Zen and the art of multiple comparisons. *Psychosom Med*. 2015;77(2):114-125. doi:10.1097/PSY.0000000000000148

58. Leech R, Sharp DJ. The role of the posterior cingulate cortex in cognition and disease. *Brain*. 2014;137(Pt 1):12-32. doi:10.1093/brain/awt162

59. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259. doi:10.1007/BF00308809

60. Aggleton JP, Pralus A, Nelson AJ, Hornberger M. Thalamic pathology and memory loss in early Alzheimer’s disease: moving the focus from the medial temporal lobe to Papez circuit. *Brain*. 2016;139(Pt 7):1877-1890. doi:10.1093/brain/aww083

61. Van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer’s disease. *Cereb Cortex*. 2000;10(3):243-251. doi:10.1093/cercor/10.3.243

62. Fu H, Possenti A, Freer R, et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. *Nat Neurosci*. 2019;22(1):47-56. doi:10.1038/s41593-018-0298-7

63. Lesuis SL, Hoeijmakers L, Korsos A, et al. Vulnerability and resilience to Alzheimer’s disease: early life conditions modulate neuropathology and determine cognitive reserve. *Alzheimers Res Ther*. 2018;10(1):95. doi:10.1186/s13195-018-0422-7

64. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. *Nat Neurosci*. 2011;14(6):750-756. doi:10.1038/nn.2801

65. Small SA, Swanson LW. A network explanation of Alzheimer’s regional vulnerability. *Cold Spring Harb Symp Quant Biol*. 2018;83:193-200. doi:10.1101/sqsb.2018.83.036889

66. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. *Clin Geriatr Med*. 2013;29(4):737-752. doi:10.1016/j.cger.2013.07.002

67. Iadecola C, Yaffe K, Biller J, et al; American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Stroke Council. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. *Hypertension*. 2016;68(6):e67-e94. doi:10.1161/HYP.0000000000000053

68. Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. *Ann NY Acad Sci*. 2015;1353:60-71. doi:10.1111/nyas.12807

69. Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. *Front Neurosci*. 2014;8:375. doi:10.3389/fnins.2014.00375

70. May A. Experience-dependent structural plasticity in the adult human brain. *Trends Cogn Sci*. 2011;15(10):475-482. doi:10.1016/j.tics.2011.08.002

71. Zatorre RJ, Fields RD, Johansen-Berg H. Plasticity in gray and white: neuroimaging changes in brain structure during learning. *Nat Neurosci*. 2012;15(4):528-536. doi:10.1038/nn.3045

72. Sala Frigerio C, De Strooper B. Alzheimer’s Disease mechanisms and emerging roads to novel therapeutics. *Annu Rev Neurosci*. 2016;39:57-79. doi:10.1146/annurev-neuro-070815-014015
SUPPLEMENT.
eAppendix. Supplemental Methods
eReferences
eFigure 1. Distributions of Continuous Variables in the UK Biobank and ADNI Cohorts
eTable 1. Correlation Coefficients in Multivariable Analysis for Age and Modifiable Risk Factors for Dementia
eFigure 2. Gray Matter Regions With Volumes Associated With Sex
eFigure 3. Associations of Cognitive Performance With Modifiable Factors-Related Brain Regions
eTable 2. Associations of Cognitive Test Scores With Modifiable Risk Factors for Dementia and Age